Course Summary This issue of Rheumatology Nurse Practice will explore the growing base of knowledge regarding the pathophysiology of RA and how new agents being […]
Course Category: Rheumatology Nurse Practice
The Importance of Assessing Disease Activity in PsA: A Look at Our Options
The Importance of Assessing Disease Activity in PsA: A Look at Our Options TARGET AUDIENCE This activity has been designed to meet the educational needs […]
What to Do About Drug Adherence? Developing Strategies to Help Our Patients Stay on the Right Path
In this issue of Rheumatology Nurse Practice, we’ll follow a hypothetical patient from the moment they leave the rheumatology office with a DMARD prescription, tracing their steps to their insurance company, their local pharmacy (or specialty pharmacy), and their home.
Updates in RA, PsA, and Biosimilars: A Pipeline View for the Clinical Nurse
The goal of this activity is to increase awareness in targeted treatments for rheumatoid arthritis (RA) and psoriatic arthritis (PsA), as well as the potential impact of biosimilar medicines in rheumatology clinical practice.
What Does the Future Hold in the Treatment of PsA
In this issue we will explore the pathways that new agents under investigation for the treatment of psoriatic arthritis (PsA) are targeting. We will also examine the potential role of biosimilars for patients with PsA as they are introduced more commonly into clinical care.
The Impact of Obesity in Patients with Rheumatoid Arthritis
We will look at the association between obesity and rheumatoid arthritis and how the presence of excess weight impacts patient experience and response to disease modifying anti-rheumatic drug therapy. We will also briefly address current thinking surrounding the “obesity paradox.” Lastly, we will explore approaches to weight loss in patients who are overweight or obese and the general benefits of weight loss in this population.
New Agents, New Targets: How Recently Approved Biologics Are Shifting the Pendulum of Care in Psoriatic Arthritis
We will take a look at current and anticipated guideline recommendations for treatment of PsA, the efficacy and safety of biologic and other agents, considerations in the selection and switching of therapy, and real-life practice trends.
Drop the Anchor? DMARD Monotherapy for the Treatment of RA
We will explore the current body of evidence addressing the use of DMARD monotherapy, specifically biologic and targeted synthetic small molecule therapies, in patients with RA. What do the guidelines say about when to prescribe biologics or small molecules, and is monotherapy with these medications ever recommended?
Psoriatic Arthritis – Pathophysiology 101
We will examine the pathophysiology of psoriatic arthritis, focusing on epidemiology, pathogenesis, and common presenting features of the disease. We’ll also review data reflecting the current diagnostic ability among rheumatology and dermatology providers.